Markets & Regulations

© Getty Images

Finch halts biotherapeutic trial and axes 95 per cent of its staff

By Liza Laws

Finch Therapeutics announced its shock decision to discontinue the PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection (CDI) yesterday (Jan 25) saying instead it will focus on ‘realizing the value of its intellectual property estate and...

© Kira-Yan / Getty Images

Pfizer gets Paxlovid order boost from US and China

By Ben Hargreaves

Pfizer receives additional orders for its COVID-19 treatment, after US requests more doses, and several Chinese companies are also reported to have begun selling the product.

© monsitj / Getty Images

Vial secures $67m in funding for biotech-focused CRO

By Ben Hargreaves

The CRO focuses its services towards biotechs by stating that they are cheaper and more efficient compared to rivals, and it was this principle that drew in General Catalyst to provide investment.

Follow us

Products

View more

Webinars